Embecta Corp. (EMBC)
| Market Cap | 534.76M |
| Revenue (ttm) | 1.08B |
| Net Income (ttm) | 139.50M |
| Shares Out | 59.22M |
| EPS (ttm) | 2.36 |
| PE Ratio | 3.83 |
| Forward PE | 3.23 |
| Dividend | $0.60 (6.65%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 779,981 |
| Open | 9.32 |
| Previous Close | 9.24 |
| Day's Range | 9.03 - 9.35 |
| 52-Week Range | 8.47 - 15.55 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 18.50 (+104.87%) |
| Earnings Date | May 5, 2026 |
About EMBC
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. [Read more]
Financial Performance
In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EMBC stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 104.87% from the latest price.
News
embecta to Report Fiscal Second Quarter Financial Results
PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medica...
Embecta Rallies After UK Firm Deal Worth $200 Million
This strategic move aims to enhance Embecta's capabilities in drug-delivery systems.
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based med...
embecta names new Chairman of the Board and Lead Independent Director
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $261M, down slightly year-over-year, with U.S. declines offset by strong international growth. Guidance for FY2026 is reaffirmed but expected near the lower end due to U.S. pricing headwinds, while international performance and GLP-1 opportunities remain strong.
Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding s...
embecta to Report Fiscal First Quarter Financial Results
PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Transcript: 44th Annual J.P. Morgan Healthcare Conference
A global leader in diabetes injection supplies is transforming into a broader medical supplies and drug delivery company, focusing on organic growth, M&A, and brand transition. Financial flexibility is increasing through debt reduction, while new products and partnerships target emerging opportunities and market resilience.
embecta to Participate at the J.P. Morgan 2026 Healthcare Conference
PARSIPPANY, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P.
Embecta Earnings Call Transcript: Q4 2025
Solid FY25 execution with strong cash flow and debt reduction, despite revenue declines from U.S. and China headwinds. FY26 guidance anticipates flat to slightly lower revenue, margin pressure from cannula costs, and continued investment in GLP-1 partnerships and innovation.
Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance
PARSIPPANY, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelv...
embecta announces changes to Board of Directors
PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
embecta Announces Major New Commitment to Direct Relief on World Diabetes Day
PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced...
embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results
PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Transition to a standalone company is complete, with strong Q3 results and progress on debt reduction. Growth initiatives, especially in GLP-1 co-packaging, are advancing, and the business is shifting focus to operational optimization and diversification.
embecta to Participate in Investor Events
PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Earnings Call Transcript: Q3 2025
Q3 revenue hit a record $295.5M, driven by strong U.S. results and successful brand transition. Guidance for margins and EPS was raised, with debt reduction ahead of schedule and free cash flow generation strengthening. China faces headwinds from local competition and geopolitics.
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine m...
embecta to Report Fiscal Third Quarter 2025 Financial Results
PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Management highlighted successful post-spin execution, exceeding initial financial targets, and outlined a cautious but stable outlook with new growth from GLP-1s and international markets. Free cash flow is set to improve as separation costs subside, supporting debt reduction and future expansion.
Embecta Transcript: Jefferies Global Healthcare Conference 2025
The company expects flat overall revenue through 2028, with new distribution agreements and GLP-1 partnerships offsetting declines in legacy syringe and contract manufacturing. Margins may decline due to tariffs and R&D, but strong free cash flow will support debt reduction and dividends.
Embecta Transcript: Investor Day 2025
Embecta is executing a multi-phase strategy to transform from an insulin injection leader to a broad-based medical supplies company, focusing on core business strength, expansion into adjacent markets, and financial flexibility. The long-range plan targets stable margins, significant debt reduction, and new growth from GLP-1 partnerships and market-appropriate products.
embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day
PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its ina...
Embecta Earnings Call Transcript: Q2 2025
Q2 revenue exceeded expectations but declined year-over-year due to timing effects and inventory adjustments. Guidance was lowered for constant currency revenue but raised for operating and EBITDA margins, with cost savings from restructuring and debt reduction initiatives supporting profitability.